NYHA class III/IV Dilated (ischemic or idiopathic) cardiomyopathy Sinus rhythm >/= 55 bpm QRS >/= 120 ms PR interval >/= 150 ms ...

Advanced CHF is present when a patient with a diagnosis of heart failure has severe symptoms of breathlessness (NYHA Class III or worse) and/or resistant fluid retention requiring frequent ...

A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA, shortly after it showed preliminary signs of efficacy in a phase 1 trial.

1-5 To improve functional status among patients with HF, research began to explore ID as a potential clinical target over 20 years ago. 6-11 Since then, a breadth of randomized clinical trials and ...

DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an ...

This investigational therapy has been evaluated in two large placebo-controlled randomized studies in patients with chronic HFrEF. These consisted of a trial with 537 NYHA class II/III treated ...

These consisted of a trial with 537 NYHA class II/III treated patients (DREAM-HF) 2 and a 159-patient trial in end-stage HFrEF patients implanted with a left ventricular assist device (LVAD).

rate of cardiovascular deaths or hospitalizations for HF, was 12.8 events per 100 patient-years in the sacubitril/valsartan group vs. 14.6 events per 100 patient-years in the valsartan group (p = not ...

Patients who have heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and high body mass index ...

Heart failure outcomes in patients with type 2 diabetes receiving once-weekly exenatide are affected by left ventricular ejection fraction.